Ignite Creation Date:
2025-12-24 @ 11:48 PM
Ignite Modification Date:
2026-05-21 @ 6:32 PM
Study NCT ID:
NCT02268851
Status:
COMPLETED
Last Update Posted:
2024-11-15
First Post:
2014-10-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
14-396
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None